A Call to Action: A Mea Non Culpa by Big Pharma
A review of the book 'A Call to Action' by Pfizer CEO Dr. Hank McKinnell. This review focuses on the 10 action items McKinnell promulgates. Notwithstanding an Amazon.com review of the book written by Peter Rost -- Pfizer's whistleblowing head of endocrine care marketing unit -- in which McKinnell is described as making 'an impressive mea culpa,' this book is actually a mea non culpa! Find out why..
Translate Industry Trends into the Optimal Promotional Strategy
This is a summary of a recent presentation by David L. Stern, Vice President of Marketing for Metabolic and Endocrinology at Serono, Inc. Stern spoke from a marketer's perspective about recent trends in the pharmaceutical industry and how to address them by developing better marketing programs.
Marketing the Pharma Industry: The Empire Strikes Back
This article gives a spirited review of a recent Pharmaceutical Marketers Knowledgeshare Forum and includes a composite overview of the action plan developed by attendees for the pharma industry to regain trust.
To Ban or Not to Ban DTC? That Was the Question!
This article takes a critical look at Sen. Frist's proposal to reform DTC. The article includes reactions to the Frist proposal from PhRMA, AMA, advertising trade associations, and from members of the PHARMA-MKTING online discussion group.
Pharma eMarketing at Tipping Point?
Last week's ePharma Summit was held at the new Borgata Hotel and Casino in Atlantic City, NJ. This venue, it turns out, was appropriate...
HELP WANTED: Director of Drug Safety
The FDA Office of Drug Safety has a HELP WANTED sign in its window:New Leadership for Safer DrugsThe Office of Drug Safety announced a...
WLF Watches FDA Watching Drug Ads
The Washington Legal Foundation (WLF), a conservative watchdog group funded by businesses (including drug companies), last week launched the "FDA/DDMAC Watch" program to "scrutinize"...
Future of Drug Print Ads
Last week I received a special edition of Newsweek Magazine devoted to "The Future of Medicine." The issue touted new treatments coming our way...
Medicare Part D: Ramifications for the Pharmaceutical Industry at the Corporate & Product Levels
Featured Conference Medicare Part D: Ramifications for the Pharmaceutical Industry at the Corporate & Product Levels ...
CBI’s Inaugural Forum on Pharmaceutical Market Segmentation
This event is a first-in-class conference providing the only opportunity for product and brand managers, as well as those charged with marketing strategy and business development, to attend one event that addresses all their consumer marketing segmentation challenges.









